huCART19-IL18

Phase 1Biologic

UUniversity of Pennsylvania

huCART19-IL18 is one of 8 biologic programs targeting Cancers. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CancersActive, not recruiting

CancersPhase 1

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Cancers

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

2 2

Tafinlar

Novartis

Phase 2

1 3

Gleevec

Novartis

Phase 2

1 4

Mekinist

Novartis

Phase 2

1 5

Jemperli

GGlaxo Dba Glaxosmithkline

Phase 2

1 6

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Phase 2

1 7

Upifitamab Rilsodotin

MMersana Therapeutics

Phase 2

3 8

huCART19-IL18

UUniversity of Pennsylvania

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2036

Phase 1Active, not recruiting

Cancers

NCT04684563

Clinical

Trials by Indication[1]

Cancers1 trial

huCART19-IL18 in CD19+ Cancers

Active, not recruiting·UUniversity of Pennsylvania·Phase 1·NCT04684563·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for huCART19-IL18. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — huCART19-IL18 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for huCART19-IL18. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Pennsylvania company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Pennsylvania

huCART19-IL18

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2036

Trials by Indication[1]

Cancers1 trial

References

Drug Info

Quick Facts

Related News